A subset of male germ cell cancers presenting with advanced stage abundantly express the ®broblast growth factor-4 (FGF4). FGF4 expression is restricted in vitro to undierentiated embryonal carcinomas (ECs). During induced dierentiation, FGF4 expression is repressed in maturation sensitive but not resistant human ECs, suggesting FGF4 plays an important role in malignant growth or dierentiation of ECs. To explore these FGF4 signals in male germ cell cancers, the multipotent human EC NTERA-2 clone D1 (NT2/D1) cell line was studied. All-trans-retinoic acid (RA)-treatment of these cells induces a neuronal phenotype and represses tumorigenicity and FGF4 expression. In contrast, RA-treatment of retinoid resistant lines derived from NT2/D1 cells failed to repress FGF4 expression. This implicated FGF4 directly in regulating human EC growth or dierentiation. To evaluate further this FGF4 role, FGF4 was constitutively over-expressed in NT2/D1 cells using a CMV-driven expression vector containing the neomycin resistance gene. Three stable transfectants expressing exogenous FGF4 were studied as was a control transfectant only expressing the neomycin resistance gene. RA-treatment repressed endogenous but not exogenous FGF4 expression. RA-treatment of these transfectants induced morphologic and immunophenotypic maturation, changes in RA-regulated genes, and a G1 cell cycle arrest in a manner similar to parental NT2/D1 cells. This indicated FGF4 over-expression did not block RA-mediated dierentiation. As expected, RA-treatment repressed tumorigenicity of the control transfectant after subcutaneous injection into athymic mice. Despite RAtreatment, this repressed tumorigenicity was overcome in all the transfectants over-expressing FGF4. The histopathology and neovascularization did not appreciably dier between xenograft tumors derived from FGF4 over-expressing versus control transfectants. FGF4 expression studies were extended to patient-derived germ cell tumors using total cellular RNA Northern analysis and an immunohistochemical assay developed to detect FGF4 protein expression. Germ cell tumors with EC components were signi®cantly more likely to express FGF4 mRNA (P40.0179) than other examined germ cell tumors without EC components. Immunohistochemical results from 43 germ cell tumors demonstrated increased FGF4 expression especially in non-seminomas having EC components. Thus, FGF4 promotes directly malignant growth of cultured ECs, overcomes the antitumorigenic actions of RA, and is selectively expressed in speci®c histopathologic subsets of germ cell tumors. Taken together, these ®ndings indicate how dierentiation and anti-tumorigenic retinoic acid signals can be dissociated in germ cell cancer.
Introduction
The ®broblast growth factors (FGF) are a large family of structurally related growth factors with diverse function in development, dierentiation, angiogenesis, transformation and cell growth Niswander and Martin, 1993; Sakamoto et al., 1986; Taira et al., 1987; Talarico et al., 1993; Tiesman and Rizzino, 1989; Velcich et al., 1989) . These actions are mediated through speci®c members of a family of FGF receptors having tyrosine kinase activity Johnson and Williams, 1993; Mansukhani et al., 1990; . FGF4 is a ®broblast growth factor originally identi®ed in NIH3T3 transfection assays using human stomach cancer or Kaposi sarcoma derived genomic DNA (Delli Taira et al., 1987) . FGF4 expression is tightly regulated during development and FGF4 is a potential morphogen (Niswander and Martin, 1993) .
In adult and malignant tissues, FGF4 expression is tightly regulated. FGF4 expression is restricted to undierentiated murine and human embryonal carcinomas (ECs). During induced dierentiation, FGF4 expression is repressed (Miller and Rizzino, 1996; Miller et al., 1990 Miller et al., , 1993 ; Mummery et al., 1993; Scho®eld et al., 1991; Tiesman and Rizzino, 1989; Yoshida et al., 1988a, b) . FGF4 expression is repressed during induced dierentiation of maturation sensitive but not resistant human germ cell tumor cell lines . These data suggest FGF4 plays a key role in the growth or maturation states of germ cell tumors. This view is supported by the ®nding FGF4 expression occurs in a subset of clinical germ cell tumors, especially in those presenting with advanced state (Strohmeyer et al., 1991) .
This study examines directly the actions of FGF4 in regulating the growth and maturation states of human germ cell tumors. The multipotent EC cell NTERA-2 clone D1 (NT2/D1) was selected as a model since alltrans-retinoic acid (RA) treatment signals a neuronal phentotype and represses FGF4 expression and NT2/ D1 tumorigenicity (Andrews, 1984; Andrews et al., 1984 Andrews et al., , 1990 Dmitrovsky et al., 1990; Miller et al., 1990) . NT2/D1 and other human EC cells express ®broblast growth factor receptors which are regulated during retinoid induced dierentiation (Campbell et al., 1992; Pertovaara et al., 1993) . Changes in other growth factor or growth factor receptor expression occur during induced human EC dierentiation. Blocking these changes alters the growth or maturation states of these tumor cells. For instance, the epidermal growth factor receptor (EGFR) and two of its ligands, transforming growth factor-a (TGFa) and CRIPTO decline during RA-induced NT2/D1 dierentiation (Baldassarre et al., 1996; Baselga et al., 1993; Ciccodicola et al., 1989; Dmitrovsky et al., 1990; Miller et al., 1990) . Prior work reveals TGFa overexpression in NT2/D1 overcomes the anti-tumorigenic but not dierentiation-inducing eects of RA . Also, over-expression of anti-sense CRIPTO suppresses endogenous CRIPTO expression and inhibits NT2/D1 growth (Baldassarre et al., 1996) . These ®ndings indicate that the EGFR growth factor dependent autocrine loop plays a critical role in regulating tumor cell growth. These results suggest the anti-tumorigenic and dierentiation-inducing programs engaged by RA-treatment are distinct.
This study was undertaken to evaluate whether FGF4 plays an important role in the growth or dierentiation states of germ cell tumors. Recently derived RA-resistant NT2/D1 lines, NT2/D1-R1 and NT2/D1-H1 , were examined for FGF4 expression before and after RA-treatment. NT2/ D1 cells were also engineered to constitutively express exogenous FGF4, despite RA-treatment. The data reveal RA-mediated maturation of these engineered NT2/D1 cells was not blocked, as assessed by morphologic, immunophenotypic, cell cycle and differentiation markers. Unexpectedly, the anti-tumorigenic retinoid signals were overcome in all transfectants constitutively over-expressing FGF4. This indicated FGF4 promotes potently the malignant growth of these germ cell tumors. To begin to evaluate the role of FGF4 in clinical germ cell tumors, the expression of this growth factor was examined in these tumors at the mRNA and single cell immunohistochemical levels of expression. Findings were correlated with histopathology. FGF4 was found as expressed in a restricted set of clinical germ cell tumors. The ®ndings presented reveal that activation of the FGF4 dependent growth stimulatory loop uncouples retinoid-mediated growth and dierentiation signals in these human tumors.
Results
FGF4 expression is repressed in RA-treated NT2/D1 cells but not in dierentiation defective human germ cell tumor lines (Miller and Rizzino, 1996; Miller et al., 1990 Miller et al., , 1993 Mummery et al., 1993; Scho®eld et al., 1991; Tiesman and Rizzino, 1989; Yoshida et al., 1988a,b) . To determine whether FGF4 expression is also repressed in a cell previously responsive to the dierentiationinducing eects of RA, FGF4 expression was examined in NT2/D1 cells and compared to expression in recently derived retinoid resistant lines, NT2/D1-R1 and NT2/ D1-H1 . NT2/D1-R1 cells were derived from parental NT2/D1 cells after mutagenization and selection in increasing dosages of RA, as previously reported (Moasser et al., 1994 (Moasser et al., , 1995 . This cell is resistant to dierentiation and antitumorigenic RA signals (Moasser et al., 1994 (Moasser et al., , 1995 . NT2/D1-H1 cells were independently derived from NT2/D1 cells through mutagenization and selection in hexamethylene bisacetamide (HMBA) and were found to be cross-resistant to retinoids . Figure 1 demonstrates that FGF4 expression is tightly linked to eective induction of dierentiation by RA in NT2/D1 cells since FGF4 expression does not decline following RA-treatment of the RA-resistant lines, NT2/D1-R1 or NT2/D1-H1. These ®ndings were con®rmed by immunoblot analysis for FGF4 expression in NT2/D1 versus NT2/D1-R1 cells (data not shown). This lack of repressed FGF4 expression occurs while other RA-regulated genes such as the retinoic acid receptor b (RARb) are still induced (data not shown) and . This suggested FGF4 might play a causal and not coincidental role in the RAmediated growth suppression or dierentiation of NT2/ D1 cells.
To determine directly the consequences of FGF4 expression during induced NT2/D1 dierentiation, stable transfection experiments were performed. Constitutive over-expression of exogenous FGF4 was obtained in three independent NT2/D1 transfectants (designated clones 2, 3, and 4). RA-treatment of all three transfectants exhibited morphologic maturation similar to untransfected NT2/D1 cells (data not shown). Each induced RARb expression, a known marker of RA-dierentiation response in these cells (data not shown). Following RA-treatment, exogenous but not endogenous FGF4 expression was constitutive (Figure 2a ). Immuno¯uorescent activated cell sorter (FACS) analysis was performed to determine whether immunophenotypic maturation occurred in these stable transfectants, using expression of the epitope recognized by the stage speci®c embryonal antigen-3 (SSEA- Figure 1 The expression of FGF4 in retinoid sensitive (NT2/D1) versus resistant human EC lines (NT2/D1-R1 and NT2/D1-H1). This Northern analysis demonstrates that FGF4 is basally expressed in all these human EC lines but is repressed by RAtreatment only in the retinoid sensitive line, NT2/D1. A radiolabeled riboprobe for FGF4 was used in this Northern analysis, as described in the Materials and methods. The 28S ribosomal RNA is displayed to con®rm similar amounts of total RNA were added to each lane 3), a marker of the undierentiated EC cell and the antibody A2B5, recognizing a neuronal epitope induced by RA-treatment (Andrews, 1984; Andrews et al., 1984 Andrews et al., , 1990 Fenderson et al., 1987; Shevinsky et al., 1982) . As shown in Figure 3a , following RAtreatment all clones induced A2B5 expression to a similar extent. SSEA-3 expression was repressed in all clones, as expected (data not shown). No RA-resistant population of cells was identi®ed at day 6 of the induction protocol. To con®rm that each line exhibited a G1 cell cycle arrest, a known marker of RA-response in these cells , cell cycle studies were performed as depicted in Figure 3b . Cells arrested at G1 to a comparable degree in each stable transfectant, despite constitutive FGF4 expression. Thus, based on these studies, FGF4 over-expression did not block morphologic, immunophenotypic, cell cycle or gene expression markers of human EC dierentiation.
Whether constitutive FGF4 expression aected growth of these transfectants was next studied. It is reported that addition of FGF4 to cultures of human EC cells promotes proliferation, migration, and opposes apoptosis in dierentiated cells (Alanko et al., 1994 (Alanko et al., , 1996 . This indicated that FGF4 might enhance the malignant growth of EC cells. How exogenous FGF4 altered the malignant growth of NT2/D1 cells was studied, and results appear in Figure 4a and b. In each experiment 10 athymic male mice were individually injected subcutaneously with 10 7 viable cells derived from each of the described stable transfectants. As shown in Figure 4a that displays the RA-untreated xenograft tumors, the neomycin control transfectant (clone 1) formed tumors similar in latency and size to parental NT2/D1 cells . These tumors were much smaller than those formed from xenografts engineered to over-express FGF4 (clones 2 ± 4). This dierence between the control clone and those transfectants expressing constitutive FGF4 was even more evident after subcutaneous injections of RAtreated clones into athymic mice (Figure 4b ). It is known that RA-treatment markedly represses tumorigenicity of NT2/D1 but not NT2/D1-R1 cells Moasser et al., 1996) . In marked contrast to this pattern, all the FGF4 expressing clones (clones 2 ± 4) readily formed xenograft tumors, despite RA-treatment. These xenografts eventually reached sizes similar to those formed from RAa b Figure 2 (a) The constitutive expression of exogenous FGF4 in NT2/D1 cells. FGF4 was engineered as over-expressed in NT2/ D1 cells. A control clone only expressed the neomycin resistance gene (clone 1, lane 1), while three independent FGF4 overexpressing clones also expressed exogenous FGF4 (clones 2 ± 4, lanes 2 ± 4, respectively). The 28S ribosomal RNA is displayed to con®rm similar amounts of total RNA were added to each lane. (b) The con®rmation that exogenously engineered FGF4 was constitutively expressed after RA-treatment (10 mM RA) of a representative transfectant, clone 3. This demonstrates while endogenous FGF4 expression is repressed by RA-treatment, similar to what is observed in parental NT2/D1 cells, exogenous FGF4 expression was not repressed by RA-treatment. The symbols`7' and`+' refer to treatment with the vehicle DMSO (1 : 1000 dilution) versus RA-treatment (10 mM RA), respectively. The 28S ribosomal RNA is displayed to demonstrate similar amounts of total RNA were added to each lane a b Figure 3 (a) The immunophenotypic and cell cycle studies performed in FGF4 transfectants (clones 2 ± 4) and a control transfectant (clone 1). Clones 1 ± 4 were treated with or without RA (the symbol`7' refers to DMSO 1 : 1 000 dilution and`+' refers to 10 mM RA). The immunophenotype was determined by FACS analysis using techniques as described in the Materials and methods. The neuronal epitope recognized by the monoclonal antibody A2B5 was induced following RA reatment in all four clones. (b) The cell cycle analysis performed on clones 1 ± 4 revealed that RA-treatment led to the expected G1 cell cycle arrest in all examined transfectants, independent of FGF4 expression untreated cells. Following RA-treatment, the dierence in incidence between FGF4 over-expressing versus the control clone was highly signi®cant P40.001 using a non-parametric statistical analysis.
Representative tumors obtained from RA-treated and untreated xenografts were histopathologically examined. No dierences were noted between the histologic appearance or degree of maturation of these tumors (data not shown). To determine the extent of neovascularization present in these xenografts tumors, Factor VIII staining of the capillary endothelium was examined and scored. No statistical dierence was observed between the number of vessels found in the xenografts derived from FGF4 over-expressing transfectants versus the neomycin resistant control clone (data not shown).
The ®ndings that FGF4 over-expression promoted tumorigenicity of NT2/D1 cells before and after RAtreatment and that FGF4 expression was restricted to undierentiated EC cells, raised the prospect FGF4 is expressed in subsets of clinical germ cell tumors. To study this possibility, total cellular RNA was puri®ed from 45 germ cell tumors. Fifteen tumors expressed FGF4 mRNA by total cellular Northern analysis and 30 tumors did not express detectable FGF4 mRNA (Figure 5a and data not shown) . Notably, of those tumors containing EC components, 9 of 14 expressed FGF4 mRNA (P=0.0179 Fisher's Exact Test). A representative Northern analysis for FGF4 expression in these clinical tumors is shown in Figure 5a . This indicates, consistent with a prior report (Strohmeyer et al., 1991) , that FGF4 is preferentially expressed in nonseminomas but not in seminomas. To con®rm that FGF4 expression is more frequent in clinical germ cell tumors having EC components, an immunohistochemical assay was developed to detect FGF4 expression in paran-embedded tissue sections. Reactivity of this antisera is displayed in Figure 5b (a) The Northern analysis for FGF4 expression in clinical germ cell tumors. Results from two representative germ cell tumors representing pure seminoma (lane 1) and a mixed germ cell tumor with EC components (lane 2) are provided with the indicated 28S ribosomal bands. This Northern analysis demonstrates that FGF4 mRNA is abundantly expressed in the non-seminoma germ cell tumor, but not in the seminomatous tumor. (b) To extend the Northern analysis ®ndings to single cells, an immunohistochemical assay was used to detect FGF4 expression in clinical germ cell tumors. This immunohistochemical assay detects FGF4 in paran-embedded tissues. This assay demonstrates lack of FGF4 expression in the displayed seminoma and teratoma, while abundant FGF4 expression is observed in the depicted non-seminoma (arrow) expression in teratomas and seminomas, FGF4 expression in ECs is abundant (see arrow, Figure 5b ). In total, 43 germ cell tumors were examined. Only 23% of seminomas stained positively for FGF4 in more than 5% of tumor cells. In contrast, 62% of germ cell tumors having EC components stained positively for FGF4. Of the examined teratomas, only those having epithelial cell maturation exhibited FGF4 staining. These immunohistochemical ®ndings con®rm and extend the Northern analysis data revealing preferential expression of FGF4 in germ cell tumors having EC components. Thus, clinical germ cell tumors exhibit an FGF4 expression pattern similar to that observed in undierentiated cultured ECs, before RA-treatment.
Discussion
This study reports that FGF4 promotes the malignant growth of cultured germ cell cancer cells and overcomes the anti-tumorigenic actions of retinoic acid. The FGFs are a large family of growth factors with reported eects in development, dierentiation, angiogenesis, mitogenesis, and transformation Niswander and Martin, 1993; Sakamoto et al., 1986; Taira et al., 1987; Talarico et al., 1993; Tiesman and Rizzino, 1989; Velcich et al., 1989) . Of these diverse functions, FGF4 signals are especially interesting to examine in germ cell tumors since expression of FGF4 is tightly regulated during development and restricted to undierentiated ECs (Miller and Rizzino, 1996; Miller et al., 1990; Mummery et al., 1993; Scho®eld et al., 1991; Strohmeyer et al., 1991; Tiesman and Rizzino, 1989; Yoshida et al., 1988a,b) . Cell stage-speci®c expression depends on an enhancer element present 3' to FGF4 coding sequences, which contains an octamer binding site (Ambrosetti et al., 1997; Curatola and Basilico, 1990; Dailey et al., 1994; Yuan et al., 1995) . RAtreatment represses FGF4 expression in dierentiation sensitive but not resistant human ECs (Miller and Rizzino, 1996; Miller et al., 1990 Miller et al., , 1993 Mummery et al., 1993; Scho®eld et al., 1991; Tiesman and Rizzino, 1989; Yoshida et al., 1988a,b) . As shown in Figure 1 , NT2/D1 cells rendered RA resistant all fail to repress FGF4 expression, despite RA-treatment. These findings, when coupled with the fact that FGF4 expression is higher in those germ cell tumors presenting with advanced stage (Strohmeyer et al., 1991) , indicate this growth factor might play a central role in the biology of these tumors by regulating the growth or dierentiation states of germ cells cancers.
This study evaluates directly these tumor growth and maturation eects in germ cell cancer ®rst by engineering constitutive FGF4 expression in NT2/D1 cells. RA-treatment of parental NT2/D1 cells represses FGF4 expression and reduces cellular tumorigenicity when a neuronal phenotype is induced. As shown in Figure 3 the constitutive expression of FGF4 does not block RA-mediated immunophenotypic maturation, G1 cell cycle arrest, or gene expression markers. This indicates that in vitro maturation of these engineered NT2/D1 cells was not appreciably aected by FGF4. In marked contrast to these in vitro ®ndings, in vivo growth of xenograft tumors was enhanced both before and after RA-treatment, as shown in Figure 4 . The lack of observed dierentiation eects by FGF4 overexpression was previously reported for murine teratocarcinomas (Miller and Rizzino, 1996) , although the consequences of constitutive FGF4 expression on cellular tumorigencity were not comprehensively examined in this prior study.
Several explanations to account for the dierences between these in vitro and in vivo ®ndings were explored. It is interesting to note that the histopathologic features of the xenograft tumors obtained from RA-treated versus untreated NT2/D1 cells did not appear to dier. The degree of neovascularization was also not observed as dierent between these xenografts which constitutively express FGF4 or do not express exogenous FGF4. Promotion of angiogenesis did not appear to in¯uence the dierences in tumorigenicity observed between these xenografts. Thus, eects of FGF on surrounding tissue, while not established as involved, cannot be excluded as contributing to these ®ndings. Perhaps tumor cell-matrix interactions that are FGF4 dependent account for this enhanced tumorigenicity. The ®ndings reported here are consistent with reports that FGFs promote survival and growth of retinoid treated human ECs within de®ned matrix gels (Alanko et al., 1994 (Alanko et al., , 1996 . This may re¯ect the stromal changes required for xenograft growth of RA-treated NT2/D1 transfectants over-expressing FGF4 that was observed in this study. Perhaps constitutive FGF4 expression promotes survival of RA-treated NT2/D1 cells in vivo by opposing apoptosis that may occur in this setting (Alanko et al., 1996) . An alternative explanation for these ®ndings is that downstream targets of the FGF4 receptor tyrosine-kinase dependent signals antagonize actions of retinoic acid or its target genes. The ®ndings reported here are reminiscent of a survival advantage for FGF4 transfectants following irradiation (Jung et al., 1994) . FGF4 is also known to promote survival of long-term human bone marrow cultures (Quito et al., 1996) . Taken together, the ®ndings reported here extend prior work by showing how constitutive FGF4 expression in EC cells favors growth of xenograft tumors, despite RAtreatment.
Constitutive FGF4 expression antagonized the antitumorigenic eects of RA in these EC transfectants. It appears an analogous, though more prominent, uncoupling of the dierentiation-inducing from the anti-tumorigenic eects of RA is found with FGF4 than that observed previously for TGFa or CRIPTO (Baldassarre et al., 1996; Baselga et al., 1993) . This uncoupling is not without precedence since others have reported similar ®ndings in other tumor cell contexts including neuroblastomas and rhabdomyosarcomas (Bader et al., 1991; Crouch and Helman, 1991) .
Constitutive FGF4 expression promotes tumorigenicity of NT2/D1 cells before and after RA-treatment. This suggested analysis of FGF4 expression in primary germ cell tumors might highlight distinct histopathologic subsets. This view is supported by the report of increased FGF4 expression in germ cell tumors presenting with advanced clinical stage (Strohmeyer et al., 1991) . The ®ndings presented in Figure 5 indicate the preferential expression of FGF4 in those germ cell tumors containing EC components. Whether high levels of FGF4 expression in germ cell cancers resulted in an unfavorable clinical outcome could not be determined in this study due to the limited number of tumors examined for expressed FGF4.
In summary, this study reveals that constitutive FGF4 expression promotes the malignant growth of germ cell cancer without blocking retinoid-induced tumor cell maturation. That FGF4 enhances EC tumor cell growth and is expressed in speci®c subsets of clinical germ cell tumors indicate the need to identify the molecular mechanisms by which FGF4 mediates these biologic eects in germ cell cancer.
Materials and methods

Cell line and inductions protocol
The human EC cell NT2/D1 is a clonal line derived from a xenograft of TERA-2 cells (Andrews, 1984; Andrews et al., 1984) . The retinoid-resistant cell line, NT2/D1-R1, was derived from NT2/D1 cells following mutagenization and selection in increasing dosages of RA, as previously described (Moasser et al., 1994 (Moasser et al., , 1995 . These cells are resistant to RA-mediated maturation and antitumorigenic signals . The NT2/D1-H1 line was derived following mutagenization and selection in increasing HMBA dosages. It was found to exhibit dual resistance to RA . NT2/D1 and its derived or engineered cells were cultured with 10% fetal bovine serum (FBS) in high glucose Dulbecco's Modi®ed Eagles Medium (DMEM) containing 100 units/ml penicillin, 200 mg/ml streptomycin, and 2 mM glutamine with pCO 2 of 5% at 378C in humidi®ed air. Cells were induced with RA, as previously reported . In brief, cultures were maintained at high density (410 7 cells per 15 cm tissue culture plate) to retain the undierentiated phenotype . Cells were seeded at 10 7 cells per plate in fresh medium the day before induction. On the day of induction, cells were harvested and seeded at a density of 2610 6 cells per 15 cm tissue culture dish in the presence of 10 mM RA or vehicle (1 : 1000 dilution dimethyl sulfoxide, DMSO) and grown in the dark. DMSO is known not to alter the growth or dierentiation properties of NT2/D1 cells under these culture conditions . At indicated time points, total cellular RNA or protein were harvested from cells using guanidine thiocyanate and established techniques (Chirgwin et al., 1979; Miller et al., 1993) . In selected experiments, NT2/D1 cells or its engineered clones were subjected to immuno¯uorescence analysis (Moasser et al., 1994 (Moasser et al., , 1995 to assess expression of established immunophenotypic dierentiation markers of germ cell tumors.
FGF4 stable transfectants
To generate stable FGF4 transfectants in NT2/D1 cells, a full length human FGF4 cDNA cloned into the pCNCEB8 expression vector (Wellstein et al., 1990) was used. This vector contains the CMV promoter driving FGF4 expression and a cassette containing the CMV-driven neomycin resistance gene. To avoid heterogeneity within transfectants, parental NT2/D1 cells were cloned and a single clone was used for these transfection experiments. The expression vector was stably transfected into this NT2/ D1 clone using a calcium phosphate technique (Moasser et al., 1994 (Moasser et al., , 1995 . After appropriate G418 selection, independent single cell transfectants were isolated and expanded. Representative independent transfectants were analysed. Three clones expressing exongenous FGF4, and one which only expressed the neomycin resistance gene were chosen for further analysis.
Tumorigenicity assay
For the athymic mouse tumorigenicity assays, NT2/D1 or its engineered clones were cultured as described above for 6 days in medium supplemented with RA or with DMSO vehicle. After trypsinization, 10 7 trypan-blue viable cells from each treatment group were washed in medium lacking FBS or RA and injected subcutaneously into each of 10 male athymic mice. These mice were 8 ± 14 weeks of age. Tumor latencies and volumes were measured biweekly as a function of time from injection, as described previously . Mice were sacri®ced before symptoms from subcutaneous tumors arose.
Immunophenotypic and cell cycle analyses NT2/D1 cells and its derived or engineered clones were harvested by trypsinization at day 6 of the induction protocol following treatment with RA or vehicle, as described (Moasser et al., 1994 (Moasser et al., , 1995 . These cells were subjected to FACS analysis using monoclonal antibodies to antigens recognized by SSEA-3 (Shevinsky et al., 1982) , abundantly expressed in undierentiated ECs and A2B5 (Andrews, 1984; Andrews et al., 1984 Andrews et al., , 1990 ), a neuronal marker induced following RA-treatment of these cells. These antibodies were purchased from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, Iowa) and from the American Type Tissue Collection (ATTC, Rockville, Maryland), respectively. Cells were indirectly assayed with¯uorescein conjugated anti-mouse or anti-rat antibodies (as determined by the primary antibody) using standard techniques (Moasser et al., 1994 (Moasser et al., , 1995 . Fluorescence intensity of cells was measured with a¯ow cytometer. A single population of cells was gated based on the display of cells by forward and side scatter. Mean and peak¯uorescence were measured in the entire population of cells. Cell cycle studies were performed using RA treated and untreated transfectants. Cells were stained with propidium iodide and subjected to¯ow cytomery. The percentages of cells in G1, S, G2/M were determined, using established techniques .
Northern analysis and probes
Total cellular RNA was puri®ed at various time points from NT2/D1 cells and its derived or engineered clones using guanidine thiocyanate and established techniques (Chirgwin et al., 1979) . Ten mg of total cellular RNA were electrophoresed in an agarose (FMC Corp., Rockland, ME)/formaldehyde (Fischer Scienti®c, Spring®eld, NJ) gel and transferred to nitrocellulose (Schleicher and Schuell, Inc., Keene, NH) membranes, as described (Southern, 1975) . All probes used for radiolabeling were isolated from plasmids containing either a 1.4 kb SstI/HindIII cut human RARb cDNA (Brand et al., 1988) or a 0.285 kb SacI/ HindIII cut human FGF4 cDNA (Taira et al., 1987) .
Germ cell tumor analysis
Human germ cell tumors were harvested as part of an Institutional Review Board approved tissue acquisition protocol. Primary germ cell tumors were immediately frozen in liquid N 2 at the time of surgery. Tumors were dissected with a sterile scalpel, minced in a tissue homogenizer, and total RNA puri®ed, as described previously . These membranes were hybridized to radiolabeled riboprobes or to DNA probes that were radiolabeled by random priming. Hybridization and autoradiography were performed using established methods (Langenfeld et al., 1997; Moasser et al., 1994 Moasser et al., , 1995 . Tumors were scored as positive or negative for FGF4 expression if total cellular RNA Northern analysis detected or did not detect an FGF4 transcript, respectively.
Paran-embedded tumors were individually examined for FGF4 expression using a new immunohistochemical assay and appropriate dilution of a rabbit polyclonal anti-FGF4 antibody. The immunohistochemical assays were performed using established techniques (Rusch, et al., 1995) .
